Does Wellbutrin Help with Seasonal Depression?
Yes, Wellbutrin (bupropion XL) is FDA-approved and effective for preventing seasonal affective disorder (SAD), with moderate-quality evidence showing it reduces depression recurrence by 44% when started in autumn before symptoms appear.
FDA-Approved Indication
Wellbutrin XL is specifically indicated for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder 1. This is based on three placebo-controlled trials in adults with a history of major depressive disorder with an autumn-winter seasonal pattern 1.
Dosing Strategy for SAD
Start treatment in autumn (September to November) before depressive symptoms begin:
- Week 1: 150 mg once daily in the morning
- Week 2 onward: Increase to target dose of 300 mg once daily (if tolerated)
- Continue through winter season (approximately 4-6 months)
- Taper in early spring: Reduce to 150 mg daily for one week before discontinuing 1
The timing is critical—initiate 2-4 weeks before the expected onset of depressive symptoms based on the patient's historical pattern 2.
Efficacy Data
The evidence is compelling. Across three randomized controlled trials with 1,100 participants, bupropion XL demonstrated:
- Depression-free rates: 84.3% versus 72.0% for placebo (combined trials) 3
- Relative risk reduction: 44% for depression recurrence 4
- Individual trial results: Depression recurrence rates of 19% vs 30%, 13% vs 21%, and 16% vs 31% (bupropion vs placebo) 3, 4
For a population with 50% yearly recurrence risk, the number needed to treat is 5—meaning one in five patients will benefit from preventive treatment 3.
Important Safety Considerations
Monitor closely for:
- Suicidal thoughts and behaviors, especially in patients under 24 years old—this is a black box warning 1
- Seizure risk: Bupropion lowers seizure threshold; avoid in patients with seizure disorders or eating disorders 5
- Common side effects: Headache (moderate-quality evidence), insomnia and nausea (low-quality evidence) 3
Begin monitoring within 1-2 weeks of initiation for worsening depression, agitation, irritability, or unusual behavioral changes 6.
Clinical Context
Despite an average of 13 previous seasonal depressive episodes in trial participants, 60% had never been treated for depression 4. This highlights both the undertreatment of SAD and the opportunity for preventive intervention.
The predictable nature of SAD makes it uniquely suited for preventive treatment 7, 4. However, three out of four patients will not benefit from preventive bupropion treatment and will be exposed to potential adverse effects 3. This requires careful shared decision-making.
Comparison with Other Treatments
While bright light therapy is also effective for SAD 2, no head-to-head trials compare bupropion with light therapy 3. The 2008 American College of Physicians guideline notes that bupropion has lower rates of sexual adverse events compared to SSRIs like fluoxetine or sertraline 6, which may influence treatment selection for some patients.
Acute Treatment Evidence
For acute treatment of active SAD episodes (rather than prevention), evidence is more limited. One open-label study showed 67% complete response and 33% partial response with bupropion 200-400 mg/day 8, but placebo-controlled trials for acute SAD treatment are lacking 7.
Contraindications
Absolute contraindications:
- Seizure disorders
- Eating disorders (anorexia nervosa, bulimia nervosa)
- Abrupt discontinuation of alcohol or benzodiazepines
- Concurrent or recent (within 14 days) MAOI use 5, 1
Dose adjustments required:
- Moderate-to-severe hepatic impairment: Maximum 150 mg every other day
- Mild hepatic impairment: Consider dose/frequency reduction 1